Amgen Doubles Down On Less Frequent MariTide Maintenance Dosing In Obesity
Three new Phase III trials revealed in Amgen’s Q1 earnings report will test dosing every eight weeks or quarter in subjects switching from Zepbound or Wegovy or enrolled in other Phase III MariTide studies.
Scrip - April 30, 2026

Foundayo Misses Wegovy Pill’s Early Performance, But Lilly Isn’t Worried
While Foundayo’s early launch metrics appear to fall short of those for the Wegovy pill, Lilly is talking a slow, steady ramp and an eye to building the oral GLP-1 internationally.
Scrip - April 30, 2026

BMS Looks Ahead To Catalyst-Rich 2026
The drugmaker reported steady growth for Eliquis in the first quarter while anticipating several oncology and cardiovascular readouts over the course of the year.
Scrip - April 30, 2026

Merck’s Enlicitide Launch Timing Depends On CNPV Discussions
The oral PCSK9 inhibitor could be a big growth driver for Merck & Co., with a launch targeted for the second half of the year.
Scrip - April 30, 2026

PureTech Wants To Get Its Hub-And-Spoke Model Spinning Faster
The Boston-based company’s CEO hopes to generate more spin-out companies more quickly and bring in outside investors sooner.
Scrip - April 30, 2026

Leo Leaps Into Gene Therapy With Replay Acquisition
The Denmark-based medical dermatology specialist has paid $50m upfront to bag a preclinical herpes simplex virus gene therapy for the treatment of dystrophic epidermolysis bullosa.
Scrip - April 30, 2026

Executives On The Move: Kai Beckmann Takes The Helm At Merck KGaA
Recent changes in the industry include C-suite changes at Inventiva and internal moves at Amgen, plus Ardelyx gets a new chief legal officer from Bristol Myers Squibb.
Scrip - April 30, 2026

Teva Locks In Tourette’s Frontrunner With $700m Emalex Buy
Teva bets $700m upfront on a late-stage Tourette's drug that could potentially fill a treatment gap affecting half the patients with the condition.
Scrip - April 30, 2026

Astellas Braces For Xtandi LoE By Broadening Strategic Products
Astellas logs record annual revenue on the back of mainstay growth, while planning to expand Padcev’s indications in multiple markets and moving other key candidates into Phase III.
Scrip - April 30, 2026

Axoft Raises $55M To Advance Brain-Computer Interface Toward FDA Approval In 2027
Cambridge, Massachusetts-based Axoft closed a $55m Series A funding round to expand global clinical trials and pursue FDA clearance for its ultra-soft brain-computer interface designed to detect consciousness in coma patients.
Medtech Insight - May 1, 2026

US Consumer Health News Digest: Business, Regulation, Science
HBW Insight notes recent news from across the US consumer health industry and marketplace in our latest weekly digest.
HBW Insight - May 1, 2026

Xbrane Resubmits Ranibizumab In The US – Can It Succeed This Time?
Marking the latest attempt to compete in the US biosimilar Lucentis market, Sweden’s Xbrane Biopharma has once again submitted a BLA for ranibizumab to the US FDA.
Generics Bulletin - April 30, 2026

Independent Samsung Bioepis Reports Continued Quarterly Growth
Strong financials, a growing direct sales footprint, and fresh pipeline deals signal Samsung Bioepis is building for more than just another solid quarter.
Generics Bulletin - April 30, 2026

Mum’s The Word On Teva’s Tyvaso Strategy
Teva has declined to clarify plans around generic Tyvaso despite a 2018 settlement allowing market entry, as strong Phase III data in IPF boosts the drug’s potential and raises questions over a delayed entry into a potentially multi-billion-dollar market.
Generics Bulletin - April 30, 2026

Podcast: Genyro’s Adrian Woolfson On Artificial Biological Intelligence And Genome Writing
Genyro CEO Adrian Woolfson explains how Sidewinder DNA writing and “Artificial Biological Intelligence” could compress vaccine timelines and turn genome?scale design into routine biopharma infrastructure.
In Vivo - April 28, 2026